The RejuvenAir®
System, utilizing Metered Cryospray, delivers a minimally invasive medical device therapy which aims to target the underlying cause of COPD with Chronic Bronchitis
BOSTON, July 8, 2024 /PRNewswire/ -- CSA Medical Inc., developer of The RejuvenAir® System, a medical device advancing the power of liquid nitrogen spray cryotherapy, today announced the completion of patient enrollment in its SPRAY-CB pivotal trial. The SPRAY-CB study is a double-blind, sham-controlled, prospective,